N S N Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 07-07-2024
- Paid Up Capital ₹ 0.33 M
as on 07-07-2024
- Company Age 14 Year, 27 Days
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 9.99 Cr
as on 07-07-2024
- Revenue 44.74%
(FY 2020)
- Profit 98.77%
(FY 2020)
- Ebitda -2351.92%
(FY 2020)
- Net Worth 13.59%
(FY 2020)
- Total Assets 8.45%
(FY 2020)
About N S N Biotech
The Corporate was formerly known as N S N Exim Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.33 M.
The company currently has active open charges totaling ₹9.99 Cr.
Sunil Aggarwal and Raju Aggarwal serve as directors at the Company.
- CIN/LLPIN
U51909DL2010PTC210808
- Company No.
210808
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Nov 2010
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at N S N Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Aggarwal  | Director | 26-Nov-2010 | Current |
| Raju Aggarwal | Director | 26-Nov-2010 | Current |
Financial Performance of N S N Biotech.
N S N Biotech Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 44.74% increase. The company also saw a substantial improvement in profitability, with a 98.77% increase in profit. The company's net worth Soared by an impressive increase of 13.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of N S N Biotech?
In 2020, N S N Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Fair Deal Cars Private LimitedActive 18 years 4 monthsSunil Aggarwal and Raju Aggarwal are mutual person
- Nitant Fabrications Private LimitedActive 19 years 9 months
Sunil Aggarwal and Raju Aggarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Karnataka Bank Ltd. Creation Date: 30 Mar 2021 | ₹1.60 Cr | Open |
Karnataka Bank Ltd. Creation Date: 27 Jun 2016 | ₹1.50 M | Open |
Karnataka Bank Ltd. Creation Date: 28 Aug 2015 | ₹2.41 M | Open |
How Many Employees Work at N S N Biotech?
Unlock and access historical data on people associated with N S N Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of N S N Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped N S N Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
